Author

Wenyu Fu

NYU Langone HealthORCID 0000-0002-4520-1506Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

C.-J. LiuiD· 2 shared Andrew C. HechtiD· 1 shared Aubryanna HettinghouseiD· 1 shared Chao WangiD· 1 shared Chen ZhangiD· 1 shared Damien M. LaudieriD· 1 shared Elena GrossiiD· 1 shared Guozhi XiaoiD· 1 shared

Activity by Year

2019-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

C.-J. LiuORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

TNFR1-mediated senescence and lack of TNFR2-signaling limit human intervertebral disc cell repair in back pain conditions

Jennifer Gansau, Elena Grossi, Levon Rodriguez, Minghui Wang, Damien M. Laudier, Saad B. Chaudhary, Andrew C. Hecht, Wenyu Fu, Robert Sebra, C.-J. Liu, James C. Iatridis

This study identifies TNFR1-mediated senescence and limited TNFR2 signaling as barriers to intervertebral disc cell repair in back pain, suggesting immunomodulation as a therapeutic strategy.

Osteoarthritis and Cartilage · Mar 24, 2025Peer-reviewedBioengineering

Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against autoimmune diseases

Ronghan Liu, Yuehong Chen, Wenyu Fu, Shuya Wang, Yazhou Cui, Xiangli Zhao, Zi‐Ning Lei, Aubryanna Hettinghouse, Jody Liu, Chao Wang, Chen Zhang, Yufei Bi, Guozhi Xiao, Zhe‐Sheng Chen, C.-J. Liu

This study identifies Fexofenadine as an inhibitor of TNF signaling through targeting cytosolic phospholipase A2, showing therapeutic potential in autoimmune diseases.

Annals of the Rheumatic Diseases · Oct 15, 2019Peer-reviewedMolecular Biology